• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

供应决定需求?医疗支出、政治倾向、医疗成本障碍和疫苗犹豫会影响各州的 COVID-19 疫苗接种率。

Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.

机构信息

Future of Humanity Institute, University of Oxford, Oxford, UK.

Independent Researcher, CA, United States.

出版信息

Vaccine. 2022 Oct 26;40(45):6528-6548. doi: 10.1016/j.vaccine.2022.08.050. Epub 2022 Sep 8.

DOI:10.1016/j.vaccine.2022.08.050
PMID:36202641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9452439/
Abstract

OBJECTIVES

To examine predictors of state-level COVID-19 vaccination rates during the first nine months of 2021.

METHODS

Using publicly available data, we employ a robust, iteratively re-weighted least squares multivariable regression with state characteristics as the independent variables and vaccinations per capita as the outcome. We run this regression for each day between February 1 and September 21, the last day before vaccine booster rollout.

RESULTS

We identify associations between vaccination rates and several state characteristics, including health expenditure, vaccine hesitancy, cost obstacles to care, Democratic voting, and elderly population share. We show that the determinants of vaccination rates have evolved: while supply-side factors were most clearly associated with early vaccination uptake, demand-side factors have become increasingly salient over time. We find that our results are generally robust to a range of alternative specifications.

CONCLUSIONS

Both supply and demand-side factors relate to vaccination coverage and the determinants of success have changed over time.

POLICY IMPLICATIONS

Investing in health capacity may improve early vaccine distribution and administration, while overcoming vaccine hesitancy and cost obstacles to care may be crucial for later immunisation campaign stages.

摘要

目的

在 2021 年前九个月期间,研究州级 COVID-19 疫苗接种率的预测因素。

方法

使用公开可用的数据,我们采用稳健的、迭代重新加权最小二乘多元回归,以州特征作为自变量,人均接种量作为因变量。我们在 2 月 1 日至 9 月 21 日(疫苗加强针推出前的最后一天)期间的每一天运行此回归。

结果

我们发现疫苗接种率与一些州特征之间存在关联,包括卫生支出、疫苗犹豫、医疗费用障碍、民主投票和老年人口比例。我们表明,疫苗接种率的决定因素已经发生了变化:虽然供应方面的因素与早期接种率的上升最明显相关,但需求方面的因素随着时间的推移变得越来越重要。我们发现,我们的结果在一系列替代规范下通常是稳健的。

结论

供应和需求方面的因素都与疫苗接种覆盖率有关,成功的决定因素随着时间的推移而发生了变化。

政策意义

投资于卫生能力可能会改善早期疫苗的分配和管理,而克服疫苗犹豫和医疗费用障碍对于后期的免疫接种活动阶段可能至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/97f97cb2fbc1/gr24a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/a04058ebb687/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/6076fbe43e37/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/8af030889587/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/2a6bd00d04d9/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/bc2db5e7aebf/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/589e71d421e9/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/c6a9cff51b48/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/482d79ba59e4/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/3f3746c39854/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/4315832dedef/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/3fe509de6487/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/e0cd82d5a9c8/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/55949b8bd9ba/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/b29f629b9d46/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/ccbe7bb1ce9c/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/ece16ac201e5/gr16_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/003608455634/gr17_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/339906a352a4/gr18_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/a251a8c67232/gr19_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/c8714f1ab270/gr20_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/84099d04a0b5/gr21a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/9c1d44804de7/gr22a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/a690d6f9d444/gr23a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/97f97cb2fbc1/gr24a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/a04058ebb687/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/6076fbe43e37/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/8af030889587/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/2a6bd00d04d9/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/bc2db5e7aebf/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/589e71d421e9/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/c6a9cff51b48/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/482d79ba59e4/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/3f3746c39854/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/4315832dedef/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/3fe509de6487/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/e0cd82d5a9c8/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/55949b8bd9ba/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/b29f629b9d46/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/ccbe7bb1ce9c/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/ece16ac201e5/gr16_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/003608455634/gr17_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/339906a352a4/gr18_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/a251a8c67232/gr19_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/c8714f1ab270/gr20_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/84099d04a0b5/gr21a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/9c1d44804de7/gr22a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/a690d6f9d444/gr23a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c514/9452439/97f97cb2fbc1/gr24a_lrg.jpg

相似文献

1
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.供应决定需求?医疗支出、政治倾向、医疗成本障碍和疫苗犹豫会影响各州的 COVID-19 疫苗接种率。
Vaccine. 2022 Oct 26;40(45):6528-6548. doi: 10.1016/j.vaccine.2022.08.050. Epub 2022 Sep 8.
2
The impact of national income and vaccine hesitancy on country-level COVID-19 vaccine uptake.国家收入和疫苗犹豫对国家层面 COVID-19 疫苗接种率的影响。
PLoS One. 2023 Nov 2;18(11):e0293184. doi: 10.1371/journal.pone.0293184. eCollection 2023.
3
Addressing vaccine hesitancy and resistance for COVID-19 vaccines.应对 COVID-19 疫苗的犹豫和抵制。
Int J Nurs Stud. 2022 Jul;131:104241. doi: 10.1016/j.ijnurstu.2022.104241. Epub 2022 Apr 1.
4
COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey.COVID-19 疫苗犹豫和接受情况在癌症、自身免疫性疾病或其他严重合并症患者中的调查:基于互联网的横断面研究。
JMIR Public Health Surveill. 2022 Jan 5;8(1):e29872. doi: 10.2196/29872.
5
Beliefs, barriers and hesitancy towards the COVID-19 vaccine among Bangladeshi residents: Findings from a cross-sectional study.孟加拉国居民对 COVID-19 疫苗的信仰、障碍和犹豫:一项横断面研究的结果。
PLoS One. 2022 Aug 23;17(8):e0269944. doi: 10.1371/journal.pone.0269944. eCollection 2022.
6
COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States.COVID-19 疫苗犹豫不能完全解释美国各地疫苗接种覆盖率的差异。
Vaccine. 2022 Sep 2;40(37):5471-5482. doi: 10.1016/j.vaccine.2022.07.051. Epub 2022 Aug 8.
7
Factors influencing likelihood of COVID-19 vaccination: A survey of Tennessee adults.影响 COVID-19 疫苗接种意愿的因素:田纳西州成年人调查。
Am J Health Syst Pharm. 2021 May 6;78(10):879-889. doi: 10.1093/ajhp/zxab099.
8
COVID-19 Vaccine Hesitancy and How to Address It.新冠病毒疫苗犹豫及其应对措施。
Workplace Health Saf. 2022 Feb;70(2):56-62. doi: 10.1177/21650799211073525. Epub 2022 Jan 25.
9
Changes in Parental Attitudes Toward COVID-19 Vaccination and Routine Childhood Vaccination During the COVID-19 Pandemic: Repeated Cross-sectional Survey Study.新冠疫情期间父母对 COVID-19 疫苗接种和儿童常规疫苗接种态度的变化:重复横断面调查研究。
JMIR Public Health Surveill. 2022 May 13;8(5):e33235. doi: 10.2196/33235.
10
Parents' and caregivers' role toward childhood vaccination in Albania: assessment of predictors of vaccine hesitancy.阿尔巴尼亚父母及照料者在儿童疫苗接种中的角色:疫苗犹豫的预测因素评估
Ann Ig. 2023 Jan-Feb;35(1):75-83. doi: 10.7416/ai.2022.2521. Epub 2022 May 6.

引用本文的文献

1
Determinants of COVID-19 vaccination coverage in European and Organisation for Economic Co-operation and Development (OECD) countries.欧洲及经济合作与发展组织(经合组织)国家新冠疫苗接种覆盖率的决定因素。
Front Public Health. 2024 Dec 31;12:1466858. doi: 10.3389/fpubh.2024.1466858. eCollection 2024.
2
Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review.基于成本的 COVID-19 疫苗接种和支付意愿:后疫情时代的回顾。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2313860. doi: 10.1080/21645515.2024.2313860. Epub 2024 Feb 15.
3
Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).

本文引用的文献

1
Seasonal variation in SARS-CoV-2 transmission in temperate climates: A Bayesian modelling study in 143 European regions.温带气候中 SARS-CoV-2 传播的季节性变化:143 个欧洲地区的贝叶斯建模研究。
PLoS Comput Biol. 2022 Aug 26;18(8):e1010435. doi: 10.1371/journal.pcbi.1010435. eCollection 2022 Aug.
2
Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study.《美国成年人全国队列中 COVID-19 疫苗犹豫和疫苗接种的决定因素和趋势:一项纵向研究》。
Am J Epidemiol. 2022 Mar 24;191(4):570-583. doi: 10.1093/aje/kwab293.
3
Ballroom Icons and the Power to Promote COVID-19 Vaccination Among Black and Brown LGBTQ Individuals.
羟氯喹用于医护人员 COVID-19 的暴露前预防:一项随机、多中心、安慰剂对照试验 医疗保健工作者暴露反应和羟氯喹结局(HERO-HCQ)研究。
Int J Infect Dis. 2023 Apr;129:40-48. doi: 10.1016/j.ijid.2023.01.019. Epub 2023 Jan 20.
交际舞偶像与促进黑人和棕色LGBTQ群体接种新冠疫苗的力量。
Am J Public Health. 2022 Jan;112(1):17-20. doi: 10.2105/AJPH.2021.306581.
4
Counties with Lower Insurance Coverage and Housing Problems Are Associated with Both Slower Vaccine Rollout and Higher COVID-19 Incidence.保险覆盖率较低且存在住房问题的县,疫苗接种速度较慢且新冠病毒感染率较高。
Vaccines (Basel). 2021 Aug 31;9(9):973. doi: 10.3390/vaccines9090973.
5
Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England.英格兰新冠病毒谱系组成的变化及德尔塔变异株的出现
EClinicalMedicine. 2021 Jul 31;39:101064. doi: 10.1016/j.eclinm.2021.101064. eCollection 2021 Sep.
6
Lottery-Based Incentive in Ohio and COVID-19 Vaccination Rates.俄亥俄州的彩票激励与 COVID-19 疫苗接种率。
JAMA. 2021 Aug 24;326(8):766-767. doi: 10.1001/jama.2021.11048.
7
What constitutes success in the roll-out of COVID-19 vaccines?新冠疫苗的推广中,成功的标准是什么?
Lancet. 2021 Jul 10;398(10295):115-116. doi: 10.1016/S0140-6736(21)01244-7. Epub 2021 Jun 25.
8
COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.**译文**: **新冠病毒疫苗接种率因社区脆弱性而异:一项县级分析**。
Vaccine. 2021 Jul 13;39(31):4245-4249. doi: 10.1016/j.vaccine.2021.06.038. Epub 2021 Jun 17.
9
Equitable Access and Distribution of COVID-19 Vaccines for US Vulnerable Populations: Federal Health Center Program Perspective.美国弱势群体公平获取和分配新冠疫苗:联邦健康中心项目视角
Am J Public Health. 2021 Jun;111(6):1070-1072. doi: 10.2105/AJPH.2021.306267.
10
State Strategies for Addressing Barriers During the Early US COVID-19 Vaccination Campaign.美国早期新冠疫苗接种运动期间应对障碍的国家策略
Am J Public Health. 2021 Jun;111(6):1073-1077. doi: 10.2105/AJPH.2021.306241.